ERBB2 and cholangiocarcinoma: A large-scale international study of 489 patients, including 23 liver fluke-positive CCA patients, confirmed recurrent ERBB2 amplifications and TP53 mutations in liver fluke-positive cases, while non-fluke-related CCA demonstrated more frequent FGFR2 rearrangements and epigenetic IDH1/2 and BAP1 alterations [133].